Marshall Fordyce Sells 18,500 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $37.93, for a total transaction of $701,705.00. Following the transaction, the chief executive officer directly owned 198,244 shares of the company’s stock, valued at $7,519,394.92. The trade was a 8.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Tuesday, May 12th, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $36.74, for a total transaction of $679,690.00.
• On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55.

Vera Therapeutics Stock Up 2.5%

Shares of NASDAQ:VERA opened at $40.50 on Friday. The firm has a market cap of $2.91 billion, a P/E ratio of -7.31 and a beta of 0.93. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics, Inc. has a 12-month low of $19.07 and a 12-month high of $56.05. The business has a fifty day simple moving average of $36.08 and a 200 day simple moving average of $41.47.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the previous year, the company posted ($0.81) earnings per share. Analysts predict that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Institutional Trading of Vera Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its position in Vera Therapeutics by 49.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after buying an additional 1,795,537 shares during the period. Deerfield Management Company L.P. grew its holdings in shares of Vera Therapeutics by 8.8% in the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock worth $105,812,000 after purchasing an additional 293,040 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Vera Therapeutics by 11.9% in the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after purchasing an additional 379,748 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after buying an additional 600,000 shares during the period. Finally, Eversept Partners LP increased its stake in shares of Vera Therapeutics by 9.4% in the fourth quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock worth $155,581,000 after buying an additional 264,468 shares during the period. 99.21% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Jefferies Financial Group restated a “buy” rating and issued a $60.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 price objective on Vera Therapeutics in a research note on Friday, May 15th. Finally, Wolfe Research upgraded shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price for the company in a research report on Wednesday, March 11th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $78.00.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.